The field of cancer care has evolved over the past 20 years with the development of more aggressive cancer screening programs, improvement in diagnostic testing and more effective treatment options, including the incorporation of novel targeted therapies. As a result, cancer death rates are gradually declining while cancer survivorship is steadily rising. However, these benefits are offset by long term adverse effects. Among them, cardiotoxicity is a leading cause for late morbidity and mortality. While conventional chemotherapy has been known for decades to induce detrimental effects on the heart and peripheral vasculature, the novel agents might also have harmful off-target consequences.
Steven E. Lipshultz, MD, FAAP, FAHA is the Schotanus Family Professor and Chair of the Carman and Ann Adams Department...Read more
Boaz Mendzelevski, MD is a consultant cardiologists and Vice President of Cardiology for BioClinica. He provides clinical...
Giuseppe Curigliano, MD, PhD, is the Chair of the Division of Early Drug Development at European Institute of Oncology, in Milan...Read more
Dr. Yahalom is an Attending Radiation Oncologist and Member, Memorial Sloan-Kettering Cancer Center...Read more